• <var id="qfbm7"><legend id="qfbm7"></legend></var>
    <th id="qfbm7"><track id="qfbm7"></track></th>

      <dd id="qfbm7"></dd>

      <rp id="qfbm7"></rp>

      <em id="qfbm7"></em>
      掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
      客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質量反饋  人才招聘  關于我們  聯系我們
      產品中心-北京博奧森生物技術有限公司
      首頁 > 產品中心 > 一抗 > 產品信息
      RabbitAnti-phospho-Alpha synuclein (Ser129) antibody (bs-5628R)
      ~~~促銷,代碼SSY221101~~~
      訂購熱線:400-901-9800
      訂購郵箱:sales@bioss.com.cn
      訂購QQ:  400-901-9800
      技術支持:techsupport@bioss.com.cn
      說明書: 50ul  100ul  200ul
      50ul/1280.00元
      100ul/1980.00元
      200ul/2900.00元
      大包裝/詢價

      產品編號 bs-5628R
      英文名稱 phospho-Alpha synuclein (Ser129)
      中文名稱 磷酸化核突觸蛋白α抗體
      別    名 SNCA(phospho S129); alpha Synuclein (phospho S129) ;alpha-Synuclein (Phospho-Ser129); Synuclein alpha(Phospho-Ser129); SNCA; SYUA_HUMAN; Alpha synuclein; Alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid , precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease (autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha (non A4 component of amyloid precursor); Synuclein alpha; Synuclein, alpha (non A4 component of amyloid precursor); Synuclein-α; Synuclein α.  α Synuclein; α-Synuclein.
      產品類型 磷酸化抗體 
      研究領域 免疫學  神經生物學  信號轉導  細胞凋亡  轉錄調節因子  細胞骨架  
      抗體來源 Rabbit
      克隆類型 Polyclonal
      交叉反應 Human, Mouse, Rat,  (predicted: Dog, Pig, Cow, Horse, Rabbit, Sheep, )
      產品應用 WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1ug/Test IF=1:100-500 (石蠟切片需做抗原修復)
      not yet tested in other applications.
      optimal dilutions/concentrations should be determined by the end user.
      理論分子量 15kDa
      細胞定位 細胞核 細胞漿 細胞膜 
      性    狀 Liquid
      濃    度 1mg/ml
      免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human SNCA around the phosphorylation site of Ser129: MP(p-S)EE 
      亞    型 IgG
      純化方法 affinity purified by Protein A
      緩 沖 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
      保存條件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
      注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
      PubMed PubMed
      產品介紹 Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016]..

      Function:
      May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.

      Subunit:
      Soluble monomer which can form filamentous aggregates. Interacts with UCHL1. Interacts with phospholipase D and histones.

      Subcellular Location:
      Cytoplasm. Membrane. Nucleus. Cell junction, synapse. Note=Membrane-bound in dopaminergic neurons.

      Tissue Specificity:
      Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.

      Post-translational modifications:
      Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.

      Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:168601]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

      Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:605543]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.

      Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:127750]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

      DISEASE:
      Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.

      Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:168601]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

      Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:605543]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.

      Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:127750]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

      Similarity:
      Belongs to the synuclein family.

      SWISS:
      P37840

      Gene ID:
      6622

      Database links:

      Entrez Gene: 6622 Human

      Entrez Gene: 20617 Mouse

      Entrez Gene: 29219 Rat

      Omim: 163890 Human

      SwissProt: P37840 Human

      SwissProt: O55042 Mouse

      SwissProt: P37377 Rat

      Unigene: 21374 Human

      Unigene: 17484 Mouse

      Unigene: 1827 Rat



      Synuclein 包括α-Synuclein,β-Synuclein 和γ-Synuclein 是神經細胞中富含的前突觸蛋白。α-Synuclein,Alzheimer’(AD)病淀粉樣蛋白沉積的成份之一,集中分布在神經細胞的包體和突觸。在帕金森病人中發現有α-Synuclein的變異型,而γ-Synuclein與軸突病理學有關。此抗體將為Lewy小體癡呆癥、Parkinson癥、AD和其它一些神經性疾病提供有用的病理診斷。
      產品圖片
      Sample:
      RAW264.7 (Mouse) CellLysate at 40 ug
      Primary: Anti-phospho-Alpha synuclein(Ser129)(bs-5628R) at 1/300 dilution
      Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
      Predicted band size: 15 kD
      Observed band size: 15 kD
      Sample:
      Lane 1: Human SY5Y cell lysates
      Lane 2: Human U87MG cell lysates
      Lane 3: Human U251 cell lysates
      Lane 4: Human HUVEC Cell Lysates
      Lane 5: Human HELA Cell Lysates
      Lane 6: Human 293T Cell Lysates
      Primary: Anti-phospho-Alpha synuclein (Ser129) (bs-5628R) at 1/1000 dilution
      Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
      Predicted band size: 15 kDa
      Observed band size: 18 kDa
      Sample:
      Lane 1: Cerebellum (Mouse) Lysate at 40 ug
      Lane 2: Cerebrum (Mouse) Lysate at 40 ug
      Lane 3: Cerebellum (Rat) Lysate at 40 ug
      Lane 4: Cerebrum (Rat) Lysate at 40 ug
      Lane 5: SH-SY5Y (Human) Cell Lysate at 30 ug
      Lane 6: U251 (Human) Cell Lysate at 30 ug
      Lane 7: 293T (Human) Cell Lysate at 30 ug
      Lane 8: Hela (Human) Cell Lysate at 30 ug
      Primary: Anti-phospho-Alpha synuclein (Ser129) (bs-5628R) at 1/1000 dilution
      Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
      Predicted band size: 18 kD
      Observed band size: 18 kD
      Blank control (Black line): HUVEC (Black). Primary Antibody (green line): Rabbit Anti-phospho-Alpha synuclein(Ser129) antibody (bs-5628R) Dilution: 3μg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody (white blue line): Goat anti-rabbit IgG-AF647 Dilution: 1μg /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at room temperature. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
      版權所有 2004-2023 www.sznuigl.com 北京博奧森生物技術有限公司
      通過國際質量管理體系ISO9001:2008 GB/T19001-2008認證    編號:00115Q211807R1M/1100
      京ICP備05066980號-1         京公網安備110107000727號
      97国产在线高清不卡视频,成 人 黄 色 网 站 视频,国产丰满老熟女重口对白,国模gogo中国人体私拍